...
机译:Sotrastaurin,一种新型的小分子抑制蛋白激酶C:肾移植受者的首次临床结果。
Department of Nephrology, Charité University, Berlin, Germany;
Department of Nephrology, University of Heidelberg, Heidelberg, Germany;
Department of Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany;
Department of Nephrology and Transplant, University Hospital of Wales, Cardiff, Wales, UK;
Department of Nephrology, University Hospital Essen, Essen, Germany;
Nephrology Department, Ciutat Sanitaria i Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain;
Department of Surgery and Organ Transplantation, University of Padua, Padua, Italy;
Department of Nephrology and Clinical Immunology, CHU Nantes, Nantes, France;
Novartis Pharmaceuticals Corporation, East Hanover, NJ;
Novartis Pharma AG, Basel, Switzerland;
Department of Surgery, University Hospital Zurich, Zurich, Switzerland;
Calcineurin inhibitor toxicity; drug development; efficacy; mycophenolic acid; renal function; renal transplantation; safety; T-cell activation; tacrolimus;
机译:Sotrastaurin,一种新型的小分子抑制蛋白激酶C:在肾移植受体中的首次临床结果。
机译:SOTRASTAURIN,一种新型的小分子抑制蛋白激酶C:肾移植受者的第一临床结果。
机译:SOTRASTAURIN,一种新型的小分子抑制蛋白激酶C:肾移植受者的第一临床结果。
机译:使用对靶向和未明确的荧光标记的小分子激酶抑制剂的配对的细胞内信号蛋白的体内测绘的非侵入性
机译:G蛋白信号蛋白,G蛋白偶联的受体激酶2和小分子抑制剂的调节剂对Galphaq信号通路的调节。
机译:蛋白激酶C抑制剂sotrastaurin可调节T细胞功能
机译:Sotrastaurin,一种新型的小分子抑制蛋白激酶C:肾移植受者的首次临床结果。